Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

EUROIMMUN AG develops and manufactures medical laboratory reagents for the diagnosis of autoimmune and infectious diseases and allergies. It offers indications for autoimmunity, infections, allergology, antigen detection, and molecular diagnostics; autoimmunity products for rheumatology, hepatology, gastroenterology, endocrinology, neurology, nephrology, dermatology, and infertility; and infection products for immunity determination, CSF diagnostics, emerging viruses, avidity, BIOCHIP Mosaics for infectious serology, and others, as well as additional reagents for determination of acute infections.

Deepbio Co. Ltd. engages in research and development of technologies that detects and grades prostate cancer from needle biopsy images. The company was founded by Seon-Woo Kim and is headquartered in Seoul, South Korea.

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun, and Michael Tobias Stumpp on November 22, 2004 and is headquartered in Schlieren, Switzerland.

InterVenn is a life science company unlocking the value of glycoproteomics—glycosylated proteins which are responsible for driving protein function—for the development of transformational healthcare solutions. The glycoproteome is a source of life-critical information about human biology that has the potential to improve patient outcomes significantly. Still, it has remained inaccessible due to its vast complexity. InterVenn has pioneered a first-of-its-kind AI-powered platform to decode this layer of biology at a clinically meaningful scale for the first time in history. The company’s platform can produce a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and, potentially, therapeutics. Its proprietary technology platform is accessible to pharma partners seeking rich biology insights to propel their research and development efforts. Founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert & serial entrepreneur Aldo Carrascoso, InterVenn will contribute to making the new era of personalized, predictive, and preventative care a reality. For more information about InterVenn, visit www.intervenn.com.

CorVista Health is an AI-driven medical company developing a cardiac diagnostic platform. Its platform is a non-invasive point-of-care solution allowing physicians to evaluate heart function without radiation, contrast agents, injections, fasting, or exercise.

Dayou Huaxia Biomedical Group Co., Ltd., established on 2016-09-27, The business scope includes the development of biomedical technology and diagnosis and treatment technology,Technical Services,Technology Promotion,technology transfer,technical consulting;Medical Research and Experimental Development;Wholesale medical equipment(Ι,Class II),Equipment,electronic product(law,Regulations require special approval,Do not operate without approval);Import and export,Technology Import and Export,Agent import and export(Commodities that do not involve state trade management,For products involving quota licensing management, the application procedures shall be handled in accordance with relevant state regulations.).(Market entities independently choose business projects in accordance with the law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Seasun Biomaterials, Inc. provides NGS services and real time PCR based diagnostic products. Its products and services include diagnostics, therapeutics, genome sequencing, transcriptome, and metagenome. The company was founded by Hee Gyeong Park on May 20, 2012 and is headquartered in Daejeon, South Korea.

Innate Pharma SA is a biopharmaceutical company, which engages in improving oncology treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Its product pipeline include Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

KoBioLabs, Inc. engages in the research and development of the microbiome. Its product is involved in the industries such as therapeutics, diagnostics, cosmetics, agriculture, and veterinary medicine. The company was founded by Ko Gwang-Pyo on August 11, 2014 and is headquartered in Seoul, South Korea.

4D Pharma Cork Ltd., a subsidiary of 4D Pharma Plc, is an Irish company located in Dublin that provides investigation services in identifying micro biome signatures. It was founded by Kevin J. Horgan.

Part of VolitionRX Ltd., Singapore Volition Pte Ltd. is a company headquartered in Singapore that provides diagnostics services for cancer patients. Standard Capital Corp. acquired Singapore Volition Pte Ltd. on October 07, 2011 for $0.07 million.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

Holobeam Technologies creates new possibilities in cancer detection and treatment by bringing energy teleportation to the market, resulting in significant improvements in cancer and other-disease patient outcomes. Their breakthroughs enable earlier cancer detection and more effective treatment without side effects.

Tianjing Biotechnology (Hangzhou) Co., Ltd., established on 2019-06-26, Business scope includes technology development,Technical Services,technical consulting,Achievement transfer:Biotechnology,medical technology(human stem cells,Development and application of genetic diagnosis and treatment technology);Production:medicine;medicine,Pharmaceutical Intermediates,Wholesale and import and export of Class I medical devices(Except those involving the implementation of special access management measures stipulated by the state).

OTraces Inc. is a provider of advanced oncology diagnostic systems. Manufactured in Nevada and Maryland USA, the company’s CDx Chemistry System™ elevates clinical blood analysis to new levels of precision and sophistication. Designed for cost-effective operation in the clinical laboratory, the company’s instrument group advances the science of cancer detection through the analysis of blood serum. The extreme sensitivity of protein detection possible with the CDx Chemistry System is combined with a proprietary bioinformatics engine for multi-marker profiling for the presence of cancer. The company’s first test kit – the BC Sera Dx™ panel for breast cancer detection and screening has completed Phase II of its validation in Russia with very successful results and after a small final validation protocol will be released in the fall of 2013. The prostate cancer test PC Sera Dx will under go validation also this fall. Test kits for additional cancers including ovarian, prostate, colon and lung are under development.